CAMBRIDGE, Mass., April 19, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model. The data showed thatM402, in combination with gemcitabine, significantly prolonged survival and reduced metastasis as compared to groups treated with saline alone or gemcitabine alone. The results were presented by Dr. Martijn Lolkema of the Cancer Research Institute, Cambridge, UK, in a poster titled "M402, a Novel Heparin Sulfate Mimetic, Synergizes with Gemcitabine to Improve Survival and Reduce Metastasis and Epithelial-to-Mesenchymal Transition (EMT) in a Genetically Engineered Mouse Model for Pancreatic Cancer" (abstract #LB-43) on Sunday, April 18, 2010 at the 101st Annual Meeting of the American Association for Cancer Research (AACR), in Washington, D.C.
